A subsidiary of Changchun Gaoxin (000661.SZ) plans to obtain rights related to oral suspension of methyldiprogesterone acetate

Zhitongcaijing · 2d ago

Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) announced that GENSCI Singapore, a wholly-owned subsidiary of the company's holding subsidiary Jinsai Pharmaceutical, and Baosheng Pharmaceutical intend to sign an “Asset Sale Agreement” and “Supply Agreement”. Baosheng Pharmaceutical will transfer the intellectual property rights (including trademarks, etc.) of the pharmaceutical marketing license holder (MAH) held by Baosheng Pharmaceutical (“Meshia®”) worldwide other than Hungary (“scope region”) exclusive to this product GENSCI Singapore and GENSCI Singapore also authorized Prudential Pharmaceuticals to manufacture and supply this product for a long time.

Currently, the indications for which Meshya ® has been approved for marketing include: anorexia in patients with acquired immunodeficiency syndrome; significant weight loss due to cachexia in patients with acquired immunodeficiency syndrome and cancer patients. According to the agreement, GENSCI Singapore will pay 30 million US dollars as the transfer amount of intellectual property rights (including trademarks, etc.) and MAH rights in the scope and exclusive to this product. Subsequently, milestone payments based on specific events include contingent consideration as part of purchased assets of $40 million and sales milestone payments of up to $30 million.